Original Article | Published:

The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2

Oncogene volume 35, pages 49814989 (22 September 2016) | Download Citation

Abstract

A number of naturally occurring isoforms of the tumour suppressor protein p53 have been discovered, which appear to have differing roles in tumour prevention or promotion. We are investigating the tumour-promoting activities of the Δ133p53 isoform using our mouse model of Δ133p53 (Δ122p53). Here, we report that tumours from Δ122p53 homozygous mice show evidence of invasion and metastasis and that Δ122p53 promotes migration though a 3-dimensional collagen matrix. We also show that Δ122p53 and Δ133p53 promote cell migration in scratch wound and Transwell assays, similar to the ‘gain-of-function’ phenotypes seen with mutant p53. Using the well-defined B16 mouse melanoma metastatic model, we show that Δ122p53 leads to faster generation of lung metastases. The increased migratory phenotypes are dependent on secreted factors, including the cytokine interleukin-6 and the chemokine CCL2. We propose that Δ122p53 (and Δ133p53) acts in a similar manner to ‘gain-of-function’ mutant p53 proteins to promote migration, invasion and metastasis, which may contribute to poor survival in patients with Δ133p53-expressing tumours.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , . Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene 2000; 19: 5826–5830.

  2. 2.

    , , , . Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J 2002; 21: 2373–2382.

  3. 3.

    , , , . p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 2003; 278: 14414–14419.

  4. 4.

    , . Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 2004; 23: 5577–5585.

  5. 5.

    , , , . Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007; 178: 23–30.

  6. 6.

    , , , , , et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34–44.

  7. 7.

    , , . Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345–355.

  8. 8.

    , , , , , et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624–6628.

  9. 9.

    , , , , , et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18: 1815–1824.

  10. 10.

    , , , , , et al. p53Psi is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci USA 2014; 111: E3287–E3296.

  11. 11.

    , , , , , et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122–2137.

  12. 12.

    , , , , . Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007; 43: 617–623.

  13. 13.

    , , , , , et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 2008; 14: 1659–1668.

  14. 14.

    , , , , , et al. Expression of p53 isoforms in renal cell carcinoma. Chinese Med J 2009; 122: 921–926.

  15. 15.

    , , , , , et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; 11: 1135–1142.

  16. 16.

    , , , , . Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol 2013; 42: 1181–1188.

  17. 17.

    , , , , , et al. The p53 isoform, Delta133p53alpha, stimulates angiogenesis and tumour progression. Oncogene 2013; 32: 2150–2160.

  18. 18.

    , , , . Effects of Delta40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer 2013; 13: 134.

  19. 19.

    , , , , , et al. Delta122p53, a mouse model of Delta133p53alpha, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell Death Dis 2015; 6: e1783.

  20. 20.

    , , , , , et al. Hyperproliferation, cancer, and inflammation in mice expressing a Delta133p53-like isoform. Blood 2011; 117: 5166–5177.

  21. 21.

    , , , , , et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327–1341.

  22. 22.

    , , . p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209–218.

  23. 23.

    , , , , . Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'-(acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo. Int J Radiat Oncol Biol Phys 1979; 5: 1605–1609.

  24. 24.

    , , , , , et al. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J Vis Exp 2011, (56) e3089.

  25. 25.

    . Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148–149.

  26. 26.

    , , , , , et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853–2868.

  27. 27.

    , , , , . Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652–3656.

  28. 28.

    , , , , , et al. Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med 1988; 167: 1939–1944.

  29. 29.

    , , , , . B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2: 1126–1132.

  30. 30.

    , , , , , et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317–3322.

  31. 31.

    , , . Inflammation and p53: a tale of two stresses. Genes Cancer 2011; 2: 503–516.

  32. 32.

    , , , , , . A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006; 12: 3985–3992.

  33. 33.

    , , , , , et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 2010; 29: 1997–2004.

Download references

Acknowledgements

This work was supported by the Health Research Council of New Zealand, Marsden Fund, Maurice Wilkins Centre for Molecular Biodiscovery, Cancer Council NSW and National Health and Medical Research Council.

Author information

Author notes

    • I Roth
    •  & H Campbell

    These authors contributed equally to this work.

Affiliations

  1. Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    • I Roth
    • , M Wilson
    • , A Wiles
    • , G Williams
    • , A Woolley
    • , N Fleming
    • , M Baird
    •  & A W Braithwaite
  2. Maurice Wilkins Centre for Molecular Biodiscovery, School of Biological Sciences, University of Auckland, Auckland, New Zealand

    • I Roth
    • , M Baird
    •  & A W Braithwaite
  3. Children’s Medical Research Institute, University of Sydney, Sydney, New South Wales, Australia

    • H Campbell
    • , C Rubio
    •  & A W Braithwaite
  4. The Garvan Institute of Medical Research, Sydney, New South Wales, Australia

    • C Vennin
    •  & P Timpson
  5. Malaghan Institute for Medical Research, Wellington, New Zealand

    • M V Berridge

Authors

  1. Search for I Roth in:

  2. Search for H Campbell in:

  3. Search for C Rubio in:

  4. Search for C Vennin in:

  5. Search for M Wilson in:

  6. Search for A Wiles in:

  7. Search for G Williams in:

  8. Search for A Woolley in:

  9. Search for P Timpson in:

  10. Search for M V Berridge in:

  11. Search for N Fleming in:

  12. Search for M Baird in:

  13. Search for A W Braithwaite in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to A W Braithwaite.

Supplementary information

Glossary

FBS

foetal bovine serum

FL

full-length

IL-6

interleukin-6

MEF

mouse embryonic fibroblast

PDAC

pancreatic ductal adenocarcinoma

TP53

human p53 gene

WT

wild type

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2016.45

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)

Further reading